Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

(StatePoint) Forty-two percent of women experience sexual dysfunction -- and Hypoactive Sexual Desire Disorder (HSDD) -- characterized as frustrating low libido, is the most common form of it. It is ...

Please provide your email address to receive an email when new articles are posted on . Many midlife women experience hypoactive sexual desire disorder, which can impact both relationships and mental ...

Please provide your email address to receive an email when new articles are posted on . Hypoactive sexual desire disorder is lack of motivation, desire, response or inability to keep interest in sex.

Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...

On Dec. 15, Sprout Pharmaceuticals received approval to use its pill, Addyi (flibanserin), to treat low sexual desire in women who are past menopause. Addyi works by addressing neurotransmitters like ...

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual ...

About one in five women who reach menopause lists a loss of libido, or sex drive, as a symptom, along with difficulties with ...

As a new documentary shows how hard it was to launch a pill for female sexual dysfunction, women share how low desire affects ...